<p>Iterum Therapeutics plc is facing potential delisting from the Nasdaq Capital Market after receiving notices from the exchange regarding non-compliance with several continued listing requirements. The company failed to meet the minimum Market Value of Listed Securities (MVLS) of $35 million for 30 consecutive business days, as required by Nasdaq Listing Rule 5550(b)(2). Additionally, Iterum Therapeutics remains out of compliance with the minimum $1.00 bid price required under Nasdaq Listing Rule 5550(a)(2). If the company does not regain compliance by the specified deadlines, its securities may be subject to delisting, though it may appeal any delisting determination. The notifications currently have no immediate effect on the company’s listing status. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iterum Therapeutics plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-317728), on December 12, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here</p>

ITRM

<p>Iterum Therapeutics plc risks delisting from Nasdaq due to non-compliance with listing rules, failing to meet the $35 million MVLS and $1.00 bid price requirements. The company has received notices but can appeal any delisting decision. Current listing status remains unaffected.</p>

Iterum Therapeutics Faces Nasdaq Delisting Risk Over Listing Rule Noncompliance